J. Leurs

发表

Different effects of low-dose transdermal and oral oestrogen therapy on procarboxypeptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: A randomised, placebo-controlled study

C. Stehouwer, W. M. van Baal, P. Kenemans, 2005, Thrombosis and Haemostasis.

Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)

V. Nerme, J. Björkman, C. Mattsson, 2002, Thrombosis and Haemostasis.

Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate.

R. Verkerk, J. Willemse, D. Hendriks, 2005, Analytical biochemistry.

Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo‐ controlled, 12‐week study in early postmenopausal women

C. Stehouwer, W. M. van Baal, P. Kenemans, 2002, Journal of internal medicine.

Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

D. Hendriks, J. Leurs, 2005, Thrombosis and Haemostasis.

Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold‐dependent mechanism

V. Nerme, D. Hendriks, Y. Sim, 2004, Journal of thrombosis and haemostasis : JTH.

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

P. Kenemans, T. Vogelvang, J. C. Netelenbos, 2004, Menopause.

Nationwide Harmonization Effort for Semi-Quantitative Reporting of SARS-CoV-2 PCR Test Results in Belgium

P. Maes, B. Bearzatto, E. André, 2022, Viruses.

Thrombin-activatable fibrinolysis inhibitor aka procarboxypeptidase U

M. Nesheim, D. Hendriks, J. Leurs, 2006 .

arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis

F. Goossens, R. Verkerk, J. Michiels, 2001 .

LETTERS TO THE EDITOR: Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma

J. Willemse, D. Hendriks, J. Leurs, 2005, Journal of thrombosis and haemostasis : JTH.

Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma

R. Verkerk, M. Strömqvist, D. Hendriks, 2001, Thrombosis and Haemostasis.

No correlation between time-linked plasma and CSF Aβ levels

P. Deyn, S. Engelborghs, W. Blomme, 2009, Neurochemistry International.

Development of a Genotype 325–Specific proCPU/TAFI ELISA

Els Brouwers, Ann Gils, A. Gils, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

S. Engelborghs, W. Blomme, J. Leurs, 2010, Journal of Alzheimer's disease : JAD.

Carboxypeptidase U at the interface between coagulation and fibrinolysis.

F. Goossens, R. Verkerk, J. Michiels, 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma

P. Björquist, V. Nerme, D. Hendriks, 2003, Thrombosis and Haemostasis.

HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women

T. Vogelvang, V. Mijatovic, M. J. van der Mooren, 2005, Journal of thrombosis and haemostasis : JTH.

Fast Homogeneous Assay for Plasma Procarboxypeptidase U

F. Goossens, Y. Kasahara, D. Hendriks, 2001, Clinical chemistry and laboratory medicine.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

S. Engelborghs, W. Blomme, J. Leurs, 2010, Journal of Alzheimer's disease : JAD.